Cerebrolysin Prevents Brain Injury in a Mouse Model of Liver Damage.

Morega S, Cătălin B, Simionescu CE, Sapalidis K, Rogoveanu I

Brain sciences9 Dec 2021Cited by 11 (Europe PMC)

PMID34942925PMCIDPMC8699728DOI10.3390/brainsci11121622PepBankPUB-34942925

Summary

Liver damage can lead to secondary organ damage by toxic substances and catabolic products accumulation which can increase the permeability of blood-brain barrier, leading to cognitive impairment. The only real treatment for end stage liver failure is grafting. With some, but not all, neurological symptoms subsiding after transplantation, the presence of brain damage can impair both the short and long-term outcome. We tested if Cerebrolysin can prevent brain injury in an experimental model of non-viral liver damage in mice. Behavior, abdominal ultrasound evaluation and immunohistochemistry were used to evaluate the animals. No ultrasound or behavior differences were found between the control and treated animals, with both groups displaying more anxiety and no short-term memory benefit compared to sham mice. Cerebrolysin treatment was able to maintain a normal level of cortical NeuN⁺ cells and induced an increase in the area occupied by BrdU⁺ cells. Surprisingly, no difference was observed when investigating Iba1⁺ cells. With neurological complications of end-stage liver disease impacting the rehabilitation of patients receiving liver grafts, a neuroprotective treatment of patients on the waiting lists might improve their rehabilitation outcome by ensuring a minimal cerebral damage.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In mice with liver damage, Cerebrolysin did not change ultrasound findings versus controls.
In plain wordsIn mice with liver damage, Cerebrolysin did not change ultrasound findings versus controls.
Peptide
Cerebrolysin
Outcome
No significant changeAbdominal ultrasound
Study
micen: not reported in source
Non-viral liver damage
Comparator
Untreated liver-damage controls
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated
Source sentences
Summary
No ultrasound or behavior differences were found between the control and treated animals, with both groups displaying more anxiety and no short-term memory benefit compared to sham mice.
1 context sentence(design, population, supporting numbers)
Summary · context
We tested if Cerebrolysin can prevent brain injury in an experimental model of non-viral liver damage in mice.
Show in the study text Report a problemFND-3494292501
02AnimalAnimal study (in vivo)Efficacy outcome
In mice with liver damage, Cerebrolysin did not change behavior versus controls.
In plain wordsIn mice with liver damage, Cerebrolysin did not change behavior versus controls.
Peptide
Cerebrolysin
Outcome
No significant changeBehavior
Study
micen: not reported in source
Non-viral liver damage
Comparator
Untreated liver-damage controls
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
No ultrasound or behavior differences were found between the control and treated animals, with both groups displaying more anxiety and no short-term memory benefit compared to sham mice.
1 context sentence(design, population, supporting numbers)
Summary · context
We tested if Cerebrolysin can prevent brain injury in an experimental model of non-viral liver damage in mice.
Show in the study text Report a problemFND-3494292502
03AnimalAnimal study (in vivo)Efficacy outcome
In mice with liver damage, both Cerebrolysin-treated and control groups showed more anxiety than sham mice.
In plain wordsIn mice with liver damage, both Cerebrolysin-treated and control groups showed more anxiety than sham mice.
Peptide
Cerebrolysin
Outcome
IncreaseAnxiety versus sham
Study
micen: not reported in source
Non-viral liver damage
Comparator
Sham mice
Outcome group
Anxiety and mood · Mental health and mood
Studied dose
Dose not stated
Source sentences
Summary
No ultrasound or behavior differences were found between the control and treated animals, with both groups displaying more anxiety and no short-term memory benefit compared to sham mice.
1 context sentence(design, population, supporting numbers)
Summary · context
We tested if Cerebrolysin can prevent brain injury in an experimental model of non-viral liver damage in mice.
Show in the study text Report a problemFND-3494292503
04AnimalAnimal study (in vivo)Efficacy outcome
In mice with liver damage, neither Cerebrolysin-treated nor control animals showed a short-term memory benefit versus sham mice.
In plain wordsIn mice with liver damage, neither Cerebrolysin-treated nor control animals showed a short-term memory benefit versus sham mice.
Peptide
Cerebrolysin
Outcome
Direction not reportedShort-term memory versus sham
Study
micen: not reported in source
Non-viral liver damage
Comparator
Sham mice
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
No ultrasound or behavior differences were found between the control and treated animals, with both groups displaying more anxiety and no short-term memory benefit compared to sham mice.
1 context sentence(design, population, supporting numbers)
Summary · context
We tested if Cerebrolysin can prevent brain injury in an experimental model of non-viral liver damage in mice.
Show in the study text Report a problemFND-3494292504
05AnimalAnimal study (in vivo)Mechanism
In mice with liver damage, Cerebrolysin maintained normal cortical NeuN-positive cell levels.
In plain wordsIn mice with liver damage, Cerebrolysin maintained normal levels of cortical nerve cells marked by NeuN.
Peptide
Cerebrolysin
Outcome
Not applicableCortical NeuN-positive cells
Study
micen: not reported in source
Non-viral liver damage
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Cerebrolysin treatment was able to maintain a normal level of cortical NeuN⁺ cells and induced an increase in the area occupied by BrdU⁺ cells.
1 context sentence(design, population, supporting numbers)
Summary · context
We tested if Cerebrolysin can prevent brain injury in an experimental model of non-viral liver damage in mice.
Show in the study text Report a problemFND-3494292505
06AnimalAnimal study (in vivo)Mechanism
In mice with liver damage, Cerebrolysin increased the area occupied by BrdU-positive cells.
In plain wordsIn mice with liver damage, Cerebrolysin increased the area occupied by cells marked by BrdU.
Peptide
Cerebrolysin
Outcome
IncreaseBrdU-positive cell area
Study
micen: not reported in source
Non-viral liver damage
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Cerebrolysin treatment was able to maintain a normal level of cortical NeuN⁺ cells and induced an increase in the area occupied by BrdU⁺ cells.
1 context sentence(design, population, supporting numbers)
Summary · context
We tested if Cerebrolysin can prevent brain injury in an experimental model of non-viral liver damage in mice.
Show in the study text Report a problemFND-3494292506
07AnimalAnimal study (in vivo)Mechanism
In mice with liver damage, Cerebrolysin did not change Iba1-positive cells versus controls.
In plain wordsIn mice with liver damage, Cerebrolysin did not change cells marked by Iba1 versus controls.
Peptide
Cerebrolysin
Outcome
No significant changeIba1-positive cells
Study
micen: not reported in source
Non-viral liver damage
Comparator
Untreated liver-damage controls
Outcome group
Inflammation markers · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Surprisingly, no difference was observed when investigating Iba1⁺ cells.
1 context sentence(design, population, supporting numbers)
Summary · context
We tested if Cerebrolysin can prevent brain injury in an experimental model of non-viral liver damage in mice.
Show in the study text Report a problemFND-3494292507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.